|
|
|
|
Дата |
|---|
| 05.12.2025 |
| 04.12.2025 |
| 03.12.2025 |
| 02.12.2025 |
| 01.12.2025 |
| 28.11.2025 |
| 26.11.2025 |
| 25.11.2025 |
| 24.11.2025 |
| 21.11.2025 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
13.08
|
13.91
|
12.33
|
12.33
|
13.77
|
13.59
|
|
|
685 259.00
|
693.00
|
|
12.26
|
12.92
|
12.00
|
11.96
|
12.80
|
12.40
|
|
|
245 292.45
|
388.00
|
|
11.75
|
11.92
|
10.43
|
10.43
|
12.05
|
11.895
|
|
|
286 238.46
|
587.00
|
|
10.01
|
10.40
|
9.50
|
9.25
|
9.64
|
9.27
|
|
|
297 351.54
|
426.00
|
|
9.28
|
10.77
|
9.96
|
9.28
|
9.96
|
9.52
|
|
|
291 371.84
|
546.00
|
|
9.67
|
10.88
|
9.88
|
9.85
|
10.35
|
9.99
|
|
|
180 954.32
|
290.00
|
|
9.28
|
10.00
|
9.38
|
9.31
|
9.70
|
9.66
|
|
|
166 752.13
|
384.00
|
|
9.30
|
10.08
|
9.50
|
9.34
|
9.505
|
9.35
|
|
|
54 942.76
|
181.00
|
|
9.28
|
10.00
|
9.40
|
9.40
|
9.52
|
9.50
|
|
|
61 795.44
|
232.00
|
|
8.98
|
10.00
|
9.50
|
8.86
|
9.50
|
9.37
|
|
|
401 660.27
|
660.00
|
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation.
It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
Показать все Скрыть